The drug, recognized to inhibit c-kit, can be used to treat chronic myelogenous leukemia and other cancers currently. Positron emission tomography scans demonstrated that Gleevec halved the metabolic activity of the tumors, while afterwards examination verified that the tumors were much smaller than in placebo-treated mice. We found there is a requirement from the disease fighting capability to connect to the tumor for the tumor to grow, Dr. Parada stated. When mast cells are blocked, the tumor cannot grow. During these experiments, the researchers learned about a woman who had a big neurofibroma that could not be removed surgically because way too many blood vessels were involved.‘No single institution has a sufficient quantity of patients or assets to conduct the studies and analyze the info to discover who is at risk for SUDEP and just why,’ said GQ Zhang, PhD, Case School of Engineering and CWRU College of Medicine, and Principal Investigator of the Informatics and Data Analytics Core of the guts. ‘Just through collaboration among multiple sites can clinicians and scientists gather plenty of physiological, imaging, genomic and other data to understand the causes and develop treatment ways of prevent SUDEP.’ Added Vicky Whittemore, PhD, NINDS plan director and a leader of the Center: ‘These projects represent an array of strategies for figuring out what causes SUDEP and identifying risk elements that may help prevent it.’ The award marks an extremely successful collaboration between Lhatoo at the Epilepsy Center at UH Case Medical Center, Zhang in the Division of Medical Informatics, CWRU College of Medicine, and co-investigator Kenneth Loparo, PhD, from the Department of Electrical Engineering and Computer Sciences at the CWRU College of Engineering.